Much of the debate surrounding counterfeit medicines to date has focused on how to prevent them seeping into the supply chains of developed-country markets. The majority of counterfeit medicines originate in Less Developed Countries (LDCs), including most of those that end up in the US and EU. Steps should be taken to change the incentives faced by counterfeiters in LDCs participating in the production and trade of counterfeit pharmaceuticals.